Pitcairn Co. Sells 273 Shares of DaVita Inc. (NYSE:DVA)

Pitcairn Co. decreased its position in shares of DaVita Inc. (NYSE:DVA) by 5.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,175 shares of the company’s stock after selling 273 shares during the period. Pitcairn Co.’s holdings in DaVita were worth $602,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVA. Nordea Investment Management AB lifted its holdings in shares of DaVita by 96.6% during the third quarter. Nordea Investment Management AB now owns 1,038,086 shares of the company’s stock worth $125,682,000 after purchasing an additional 510,106 shares during the period. Bank of Montreal Can raised its stake in DaVita by 17.6% during the second quarter. Bank of Montreal Can now owns 776,956 shares of the company’s stock worth $94,883,000 after buying an additional 116,008 shares during the last quarter. Legal & General Group Plc raised its stake in DaVita by 1.2% during the second quarter. Legal & General Group Plc now owns 619,554 shares of the company’s stock worth $74,613,000 after buying an additional 7,626 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in DaVita by 12.7% in the second quarter. UBS Asset Management Americas Inc. now owns 593,923 shares of the company’s stock valued at $71,526,000 after purchasing an additional 66,702 shares in the last quarter. Finally, Harvard Management Co. Inc. bought a new stake in DaVita in the second quarter valued at $49,245,000. Institutional investors and hedge funds own 86.54% of the company’s stock.

Several research analysts recently weighed in on DVA shares. Truist boosted their price target on shares of DaVita from $114.00 to $125.00 and gave the stock a “hold” rating in a report on Wednesday, January 5th. Royal Bank of Canada decreased their target price on shares of DaVita from $113.00 to $111.00 and set a “sector perform” rating on the stock in a report on Friday, October 29th. Truist Securities increased their price target on shares of DaVita from $114.00 to $125.00 and gave the stock a “hold” rating in a report on Wednesday, January 5th. Zacks Investment Research raised shares of DaVita from a “sell” rating to a “hold” rating and set a $121.00 price target on the stock in a report on Tuesday, January 4th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of DaVita from $164.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, November 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, DaVita has an average rating of “Hold” and a consensus target price of $130.13.

In other DaVita news, Director Pamela M. Arway sold 446 shares of the firm’s stock in a transaction dated Tuesday, November 23rd. The shares were sold at an average price of $102.86, for a total transaction of $45,875.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.00% of the company’s stock.

DaVita stock opened at $116.32 on Friday. The stock has a market cap of $11.85 billion, a P/E ratio of 13.54, a PEG ratio of 1.17 and a beta of 1.24. The company has a debt-to-equity ratio of 6.60, a current ratio of 1.62 and a quick ratio of 1.58. DaVita Inc. has a 1 year low of $94.38 and a 1 year high of $136.48. The firm’s 50 day moving average price is $106.73 and its 200-day moving average price is $116.28.

DaVita (NYSE:DVA) last released its earnings results on Thursday, October 28th. The company reported $2.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.26 by $0.10. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.91 billion. DaVita had a net margin of 8.33% and a return on equity of 67.99%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $1.80 EPS. As a group, equities analysts expect that DaVita Inc. will post 8.89 EPS for the current year.

About DaVita

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Recommended Story: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.